Polycystic Kidney Disease - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 93 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Polycystic Kidney Disease - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Polycystic Kidney Disease - Pipeline Review, H2 2014', provides an overview of the Polycystic Kidney Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Polycystic Kidney Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Polycystic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Polycystic Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Polycystic Kidney Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Polycystic Kidney Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Polycystic Kidney Disease Overview 9
Therapeutics Development 10
Pipeline Products for Polycystic Kidney Disease - Overview 10
Pipeline Products for Polycystic Kidney Disease - Comparative Analysis 11
Polycystic Kidney Disease - Therapeutics under Development by Companies 12
Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes 14
Polycystic Kidney Disease - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Polycystic Kidney Disease - Products under Development by Companies 19
Polycystic Kidney Disease - Products under Investigation by Universities/Institutes 20
Polycystic Kidney Disease - Companies Involved in Therapeutics Development 21
Plexxikon Inc. 21
Ipsen S.A. 22
Pfizer Inc. 23
Synta Pharmaceuticals Corp. 24
Metabolic Solutions Development Company, LLC 25
IC-MedTech, Inc. 26
Endocyte, Inc. 27
ManRos Therapeutics 28
DiscoveryBiomed, Inc. 29
Otsuka Holdings Co., Ltd. 30
Kadmon Corporation, LLC 31
Polycystic Kidney Disease - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 37
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
tolvaptan - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
tolvaptan - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
lanreotide acetate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
bosutinib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
KD-020 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
KD-019 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GLG-302 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
(ascorbic acid + menadione) - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MSDC-0160 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MSDC-0602 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
EC-0371 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecule to Inhibit CKD for Polycystic Kidney Disease - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecule to Inhibit Raf Kinase for Polycystic Kidney Disease - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
STA-2842 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecule to Inhibit EnaC for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecule for Polycystic Kidney Disease - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Drugs Targeting CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Drugs for Polycystic Kidney Disease - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
pyrimethamine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Drugs to Inhibit Vasopressin Receptor for Polycystic Kidney Disease - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Polycystic Kidney Disease - Recent Pipeline Updates 74
Polycystic Kidney Disease - Dormant Projects 85
Polycystic Kidney Disease - Product Development Milestones 86
Featured News & Press Releases 86
Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease 86
Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease 86
May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease 87
Mar 24, 2014: Otsuka Pharmaceutical's Samsca Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease 87
Dec 27, 2013: European Medicines Agency Accepts Otsuka's Marketing Authorisation Application for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease 88
Aug 29, 2013: Otsuka Receives Complete Response Letter from U.S. Food and Drug Administration for Tolvaptan for Use in Patients with Autosomal Dominant Polycystic Kidney Disease 89
Aug 05, 2013: U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee Recommends Not to Approve Otsuka Pharmaceutical's Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease 89
Jun 03, 2013: Otsuka Pharma Submits New Drug Application In Japan For Tolvaptan For Treatment Of Autosomal Dominant Polycystic Kidney Disease 90
Apr 12, 2013: Otsuka Pharma Announces FDA Acceptance Of NDA For Tolvaptan 90
Mar 01, 2013: Otsuka Canada Pharma Updates Safety Information For Polycystic Kidney Disease Drug Samsca 90
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 93
Disclaimer 93

List of Tables
Number of Products under Development for Polycystic Kidney Disease, H2 2014 10
Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Polycystic Kidney Disease - Pipeline by Plexxikon Inc., H2 2014 21
Polycystic Kidney Disease - Pipeline by Ipsen S.A., H2 2014 22
Polycystic Kidney Disease - Pipeline by Pfizer Inc., H2 2014 23
Polycystic Kidney Disease - Pipeline by Synta Pharmaceuticals Corp., H2 2014 24
Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company, LLC, H2 2014 25
Polycystic Kidney Disease - Pipeline by IC-MedTech, Inc., H2 2014 26
Polycystic Kidney Disease - Pipeline by Endocyte, Inc., H2 2014 27
Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H2 2014 28
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed, Inc., H2 2014 29
Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 30
Polycystic Kidney Disease - Pipeline by Kadmon Corporation, LLC, H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Assessment by Combination Products, H2 2014 33
Number of Products by Stage and Target, H2 2014 36
Number of Products by Stage and Mechanism of Action, H2 2014 39
Number of Products by Stage and Route of Administration, H2 2014 41
Number of Products by Stage and Molecule Type, H2 2014 43
Polycystic Kidney Disease Therapeutics - Recent Pipeline Updates, H2 2014 74
Polycystic Kidney Disease - Dormant Projects, H2 2014 85